SPAC57A7.07c Antibody

What is SPAC57A7.07c and why is it studied in research?

SPAC57A7.07c is an uncharacterized protein found in Schizosaccharomyces pombe (strain 972/24843, fission yeast), predicted to function as a homocysteine methyltransferase. This protein is studied primarily to understand fundamental cellular processes in S. pombe, which serves as an important model organism in molecular and cellular biology research . The protein is classified under UniProt accession number P87138 and represents a target for researchers investigating yeast metabolism and protein function . As an uncharacterized protein, research using antibodies against SPAC57A7.07c can help elucidate its cellular localization, expression patterns, and potential functional roles in yeast biochemical pathways.

What are the primary applications for SPAC57A7.07c antibodies in research?

SPAC57A7.07c antibodies are primarily utilized in fundamental research applications focusing on protein detection and characterization. The main validated applications include:

• Enzyme-Linked Immunosorbent Assay (ELISA) - For quantitative detection of the protein in samples

• Western Blotting (WB) - For detection of the protein by molecular weight in cell or tissue lysates

These applications enable researchers to investigate protein expression levels, subcellular localization, and potential interactions with other cellular components. The antibodies serve as critical tools for characterizing this uncharacterized protein's role in fission yeast biology and may contribute to understanding conserved metabolic pathways across species.

How do polyclonal SPAC57A7.07c antibodies differ from monoclonal antibodies in research applications?

The commercially available SPAC57A7.07c antibodies are primarily polyclonal, which has specific research implications compared to monoclonal alternatives:

For experimental design, polyclonal SPAC57A7.07c antibodies offer advantages in detecting the native protein across multiple experimental conditions, particularly when the protein might undergo conformational changes or when maximum sensitivity is required .

What are the optimal conditions for using SPAC57A7.07c antibodies in Western blotting protocols?

When designing Western blot experiments using SPAC57A7.07c antibodies, researchers should consider the following methodological parameters:

• Sample Preparation:

  • Use standard Schizosaccharomyces pombe lysis buffers containing protease inhibitors

  • Ensure adequate denaturation using SDS and heat treatment (95°C for 5 minutes)

• Gel Electrophoresis:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Load appropriate positive controls alongside experimental samples

• Transfer and Blocking:

  • Transfer to PVDF or nitrocellulose membranes

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Antibody Incubation:

  • Primary antibody dilution: 1:500 to 1:1000 in blocking buffer

  • Incubation time: Overnight at 4°C with gentle agitation

  • Secondary antibody: Anti-rabbit IgG conjugated with HRP at 1:5000 dilution

• Detection:

  • Use ECL or similar chemiluminescent detection methods

  • Exposure time may need optimization based on protein expression levels

These conditions are based on typical protocols for polyclonal antibodies against yeast proteins and may require optimization for specific experimental requirements .

How can researchers validate the specificity of SPAC57A7.07c antibodies in their experimental systems?

Validating antibody specificity is critical for ensuring reliable experimental results. For SPAC57A7.07c antibodies, researchers should implement the following validation strategies:

• Positive and Negative Controls:

  • Use purified recombinant SPAC57A7.07c protein as a positive control

  • Use SPAC57A7.07c knockout strains as negative controls when available

• Preabsorption Testing:

  • Preincubate the antibody with excess recombinant SPAC57A7.07c protein

  • Compare detection signals between preabsorbed and non-preabsorbed antibody samples

• Orthogonal Validation:

  • Confirm results using alternative detection methods (e.g., mass spectrometry)

  • Correlate protein detection with mRNA expression data

• Cross-Reactivity Assessment:

  • Test the antibody against closely related proteins or in non-S. pombe lysates

  • Examine potential cross-reactivity with structurally similar homocysteine methyltransferases

• Molecular Weight Confirmation:

  • Verify that the detected band corresponds to the expected molecular weight

  • Assess post-translational modifications if bands of unexpected sizes are observed

Proper validation ensures that experimental observations are genuinely attributable to SPAC57A7.07c rather than non-specific binding or cross-reactivity .

What methods are recommended for optimizing immunoprecipitation experiments using SPAC57A7.07c antibodies?

For successful immunoprecipitation (IP) of SPAC57A7.07c, researchers should consider the following methodological approach:

• Lysis Buffer Selection:

  • Use mild non-denaturing buffers to preserve protein-protein interactions

  • Typical composition: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and protease inhibitors

• Antibody Coupling:

  • Pre-couple the SPAC57A7.07c antibody to Protein A beads (preferred for rabbit polyclonal antibodies)

  • Ratio: 2-5 μg antibody per 20 μL of bead slurry

• Pre-clearing Step:

  • Pre-clear lysates with Protein A beads alone to reduce non-specific binding

  • Incubate for 1 hour at 4°C with rotation

• Immunoprecipitation Conditions:

  • Incubate pre-cleared lysate with antibody-coupled beads overnight at 4°C

  • Use gentle rotation to maintain bead suspension without damaging complexes

• Washing Stringency:

  • Perform 3-5 washes with decreasing salt concentrations

  • Final wash with PBS or TBS to remove detergents

• Elution Options:

  • Mild elution: Glycine buffer (pH 2.8) with immediate neutralization

  • Denaturing elution: SDS sample buffer at 95°C for direct Western blot analysis

• Confirmation Analysis:

  • Analyze eluted samples by Western blotting or mass spectrometry

  • Include IgG control IP for comparison

This methodology can be applied to identify potential protein interaction partners of SPAC57A7.07c and characterize its functional complexes in vivo .

How can computational antibody design approaches be leveraged to improve SPAC57A7.07c antibody specificity?

Advanced computational approaches for antibody design represent a frontier in improving SPAC57A7.07c antibody specificity. Researchers can implement the following strategies:

• Structural-Bioinformatics Analysis:

  • Utilizing frameworks like RosettaAntibodyDesign (RAbD) to sample diverse sequence and structure spaces

  • Applying CDR (Complementarity-Determining Region) cluster-based constraints to optimize antibody design against SPAC57A7.07c epitopes

• Epitope Prediction and Selection:

  • Employing computational algorithms to identify immunogenic and accessible epitopes on SPAC57A7.07c

  • Prioritizing unique regions with low homology to other proteins to minimize cross-reactivity

• Affinity Maturation Simulation:

  • Running Monte Carlo plus minimization (MCM) procedures to improve binding energy

  • Optimizing either total energy or interface energy between antibody and SPAC57A7.07c

• Design Risk Ratio Assessment:

  • Calculating the frequency of recovery of specific CDR lengths and clusters divided by their sampling rate

  • Targeting design risk ratios greater than 1.0 to indicate successful design enrichment

• Molecular Docking Implementation:

  • Using methods like those developed with Alphafold2 to predict binding interactions

  • Validating predicted antigenic epitopes through in silico molecular docking before experimental testing

These computational approaches can guide rational antibody design against SPAC57A7.07c, potentially reducing experimental iterations required to achieve high specificity and affinity .

What strategies can be employed to enhance the developability of custom SPAC57A7.07c antibodies?

Enhancing antibody developability involves optimizing physical and chemical properties to improve production, stability, and functionality. For SPAC57A7.07c antibodies, researchers should consider:

• Solubility Enhancement:

  • Using in silico predictors like CamSol to identify surface-exposed residues that affect solubility

  • Introducing mutations that increase predicted solubility while maintaining binding affinity

• Structural Stability Optimization:

  • Avoiding mutation to proline (Pro) for structural integrity reasons

  • Eliminating potential deamidation sites by avoiding glutamine (Gln) and asparagine (Asn) in critical regions

  • Preventing oxidation sites by limiting methionine (Met) residues in CDRs

• Experimental Validation Pipeline:

  • Small-scale expression screening in HEK293 cells followed by Protein A purification

  • Selection of promising variants for scaled-up production and size-exclusion chromatography purification

  • Comprehensive characterization including thermal stability and aggregation propensity

• Developability Assessment Assays:

  • Implementing ammonium sulfate precipitation assays to determine relative solubility

  • Utilizing differential scanning calorimetry to assess thermal stability

  • Employing size-exclusion chromatography to evaluate aggregation tendency

These strategies can be applied to develop SPAC57A7.07c antibodies with improved expression levels, stability, and reduced aggregation propensity, making them more suitable for extended research applications .

How can high-throughput screening approaches be applied to identify novel SPAC57A7.07c-targeting antibody variants?

High-throughput screening technologies offer powerful approaches for identifying optimized SPAC57A7.07c antibodies:

• Single-Cell RNA and VDJ Sequencing:

  • Isolating SPAC57A7.07c-binding B cells through flow cytometry

  • Performing high-throughput sequencing of antibody variable regions

  • Identifying expanded clonotypes indicating immune response against the target

• Combinatorial Library Construction:

  • Creating diversity through targeted mutations in CDR regions

  • Developing phage or yeast display libraries expressing antibody variants

  • Screening against immobilized recombinant SPAC57A7.07c protein

• Affinity-Based Screening Hierarchy:

  • Primary screening using ELISA to identify binding candidates

  • Secondary validation with bio-layer interferometry to measure binding kinetics (kon, koff, KD)

  • Tertiary functional assays to assess specificity and cross-reactivity

• Advanced Epitope Binning:

  • Classifying antibodies based on their epitope recognition patterns

  • Identifying antibodies targeting unique epitopes for potential synergistic applications

  • Using sandwich ELISA formats to confirm non-competing binding

• Automated Data Analysis Workflows:

  • Implementing machine learning algorithms to identify sequence-function relationships

  • Developing predictive models to prioritize candidates for experimental validation

  • Integrating structural predictions with functional data

These high-throughput approaches can significantly accelerate the identification of high-affinity, specific antibodies against SPAC57A7.07c while reducing resource requirements compared to traditional methods .

What are common causes of false negative results when using SPAC57A7.07c antibodies, and how can they be addressed?

False negative results during SPAC57A7.07c detection can stem from various technical issues:

Methodical troubleshooting following this systematic approach can help identify and resolve the specific causes of false negative results in your experimental system .

How should researchers interpret and address cross-reactivity with other proteins when using SPAC57A7.07c antibodies?

Cross-reactivity issues require careful analysis and mitigation strategies:

• Cross-Reactivity Identification:

  • Observe unexpected bands on Western blots

  • Compare against predicted molecular weight of SPAC57A7.07c

  • Analyze band patterns in control samples lacking SPAC57A7.07c

• Systematic Confirmation:

  • Mass spectrometry analysis of detected bands to identify cross-reactive proteins

  • Sequence alignment between SPAC57A7.07c and suspected cross-reactive proteins

  • Competition assays with purified recombinant proteins

• Epitope Analysis:

  • Identify regions of high sequence similarity between SPAC57A7.07c and cross-reactive proteins

  • Assess conservation of epitopes across related species

  • Design experiments to distinguish between specific and non-specific binding

• Mitigation Strategies:

  • Increase antibody dilution to reduce non-specific binding

  • Perform more stringent washing steps

  • Pre-absorb antibody with recombinant proteins showing cross-reactivity

  • Use alternative antibodies targeting different epitopes of SPAC57A7.07c

  • Employ genetic knockdown/knockout controls as definitive validation

• Result Interpretation:

  • Document all observed cross-reactivity in laboratory records

  • Consider cross-reactivity when interpreting experimental results

  • Incorporate appropriate controls to distinguish between specific and non-specific signals

By implementing these strategies, researchers can accurately distinguish between true SPAC57A7.07c detection and cross-reactive artifacts .

What are the critical factors affecting SPAC57A7.07c antibody storage and stability, and how can researchers maximize antibody lifespan?

Proper storage and handling are essential for maintaining SPAC57A7.07c antibody functionality:

• Temperature Considerations:

  • Store stock solutions at -20°C or -80°C for long-term storage

  • Avoid repeated freeze-thaw cycles by preparing single-use aliquots

  • Working dilutions can be stored at 4°C for up to one week

• Buffer Composition Impact:

  • Standard storage buffer consists of 50% glycerol, 0.01M PBS (pH 7.4)

  • Presence of preservatives (0.03% Proclin 300) helps prevent microbial contamination

  • Glycerol prevents freezing damage and protein denaturation at -20°C

• Degradation Mechanisms and Prevention:

  • Microbial contamination: Work in sterile conditions; add sodium azide (0.02%) for working solutions

  • Denaturation: Avoid exposure to extreme pH or temperatures

  • Aggregation: Minimize agitation; centrifuge briefly before use to remove any aggregates

  • Oxidation: Limit exposure to light and oxidizing agents

• Stability Indicators:

  • Visual inspection for cloudiness or precipitation

  • Periodic validation using positive controls

  • Performance tracking over time using standardized samples

• Reconstitution Best Practices:

  • Allow antibody to reach room temperature before opening to prevent condensation

  • Reconstitute lyophilized antibodies with sterile water or recommended buffer

  • Mix gently by inversion rather than vortexing

Following these guidelines can significantly extend the functional lifespan of SPAC57A7.07c antibodies, ensuring consistent experimental results and reducing costs associated with premature antibody degradation .

How might emerging antibody engineering technologies enhance SPAC57A7.07c research applications?

Emerging antibody engineering technologies present exciting opportunities for advancing SPAC57A7.07c research:

• Synthetic Antibody Libraries:

  • Developing fully human synthetic libraries targeting SPAC57A7.07c

  • Utilizing phage or yeast display for high-throughput screening

  • Engineering antibodies with predefined properties like reduced cross-reactivity

• Affinity-Engineered Variants:

  • Creating antibody variants with tailored binding kinetics

  • Designing antibodies with improved therapeutic indices

  • Engineering reduced on-target toxicity while maintaining specificity

• Fragment-Based Approaches:

  • Developing single-domain antibodies (nanobodies) against SPAC57A7.07c

  • Creating bispecific constructs targeting SPAC57A7.07c and related proteins

  • Engineering antibody fragments with enhanced tissue penetration

• Computational Design Integration:

  • Utilizing advanced algorithms like RosettaAntibodyDesign

  • Implementing flexible-backbone design protocols with cluster-based CDR constraints

  • Designing antibodies with multiple CDRs of different length, conformation, and sequence

• Functional Modularity:

  • Engineering antibodies with modular domains for multiple detection methods

  • Creating bifunctional antibodies that both detect and modify SPAC57A7.07c

  • Developing antibody-enzyme fusion proteins for proximity-based applications

These innovative approaches could transform SPAC57A7.07c research by providing more specific, versatile, and functionally enhanced antibody reagents .

What research questions about SPAC57A7.07c function remain unanswered, and how might advanced antibody tools address these gaps?

Several critical knowledge gaps remain in understanding SPAC57A7.07c biology:

• Functional Characterization:

  • The predicted homocysteine methyltransferase activity remains unconfirmed

  • Substrate specificity and enzymatic parameters are unknown

  • Regulatory mechanisms controlling activity are uncharacterized

• Interaction Network:

  • Protein-protein interaction partners remain largely unidentified

  • Integration within metabolic pathways is poorly understood

  • Potential moonlighting functions have not been explored

• Subcellular Dynamics:

  • Precise subcellular localization patterns under different conditions

  • Potential translocation in response to cellular stresses

  • Post-translational modifications affecting localization or function

Advanced antibody tools could address these gaps through:

• Super-resolution microscopy with highly specific antibodies to determine precise subcellular localization

• Proximity labeling techniques (BioID, APEX) combined with antibody pulldowns to identify interaction partners

• Conformation-specific antibodies to detect active vs. inactive states of the protein

• PTM-specific antibodies to characterize regulation through phosphorylation, methylation, or other modifications

• Intrabodies for live-cell tracking of SPAC57A7.07c dynamics

• Rapid degradation systems (TRIM-Away) using antibodies to study loss-of-function phenotypes

These approaches would significantly advance our understanding of SPAC57A7.07c biology and potentially reveal new roles in yeast cellular processes .

How do researchers effectively compare results obtained using different SPAC57A7.07c antibody clones or lots?

When comparing results across different antibody sources, researchers should implement the following methodological approach:

• Standardized Validation Protocol:

  • Establish a core set of positive and negative controls

  • Test all antibodies simultaneously under identical conditions

  • Document specific detection parameters (exposure time, gain settings)

• Epitope Mapping Comparison:

  • Determine the specific epitopes recognized by each antibody

  • Consider how epitope differences might affect detection in various applications

  • Assess whether post-translational modifications might differentially affect recognition

• Quantitative Performance Metrics:

  • Signal-to-noise ratio calculation for each antibody

  • Detection limits determination using serial dilutions

  • Specificity assessments using knockdown/knockout validation

• Cross-Platform Standardization:

  • Develop relative calibration curves between antibody lots

  • Use purified recombinant SPAC57A7.07c as a reference standard

  • Establish normalization methods for cross-experimental comparisons

• Documentation and Reporting:

  • Record complete antibody metadata (manufacturer, lot number, clone ID)

  • Document specific optimizations required for each antibody

  • Report comparative performance to build institutional knowledge

This systematic approach allows researchers to meaningfully compare results across antibody sources, identify potential sources of variability, and establish reliable protocols for continued research .

What techniques are most effective for studying evolutionary conservation of SPAC57A7.07c using cross-species antibody approaches?

Investigating evolutionary conservation of SPAC57A7.07c requires specialized methodological considerations:

• Sequence Homology Analysis:

  • Perform phylogenetic analysis of SPAC57A7.07c homologs across fungal species

  • Identify conserved domains and epitopes for antibody targeting

  • Design experiments targeting regions with varying degrees of conservation

• Epitope Conservation Assessment:

  • Use bioinformatics tools to predict epitope conservation

  • Select antibodies targeting highly conserved regions for cross-species studies

  • Consider creating custom antibodies against conserved peptide sequences

• Cross-Reactivity Testing Protocol:

  • Systematically test SPAC57A7.07c antibodies against lysates from related species

  • Include graduated evolutionary distances (close relatives to distant ones)

  • Document detection patterns and band profiles for each species

• Validation in Heterologous Systems:

  • Express SPAC57A7.07c homologs from different species in a common system

  • Compare antibody recognition efficiency across homologs

  • Correlate detection with sequence similarity metrics

• Alternative Approaches for Distant Homologs:

  • Use epitope tagging of homologs when direct antibody detection fails

  • Employ mass spectrometry for homolog identification following immunoprecipitation

  • Consider developing species-specific antibodies for comparative studies

These methods enable researchers to track evolutionary conservation of SPAC57A7.07c structure and function across species, providing insights into fundamental biological processes conserved throughout evolution .

How should researchers design experiments to distinguish between different isoforms or post-translationally modified versions of SPAC57A7.07c?

Distinguishing between protein variants requires specialized experimental design:

• Modification-Specific Detection Strategy:

  • Develop or source antibodies specific to known post-translational modifications

  • Use enzymatic treatments (phosphatases, deglycosylases) to confirm modification-dependent detection

  • Implement 2D gel electrophoresis to separate isoforms by both size and charge

• Sample Preparation Considerations:

  • Preserve labile modifications by including appropriate inhibitors

  • For phosphorylation: phosphatase inhibitors (sodium orthovanadate, sodium fluoride)

  • For ubiquitination: deubiquitinase inhibitors (PR-619, NEM)

  • For acetylation: deacetylase inhibitors (trichostatin A, nicotinamide)

• Analytical Separation Techniques:

  • Isoelectric focusing to separate by charge differences

  • Phos-tag™ acrylamide for phosphorylated protein separation

  • Mobility shift assays to detect molecular weight changes

• Confirmatory Approaches:

  • Mass spectrometry for definitive identification of modifications

  • Mutational analysis of modification sites

  • Correlation with known stimuli that induce specific modifications

• Temporal and Contextual Analysis:

  • Time-course experiments to track modification dynamics

  • Comparison across different growth conditions or stresses

  • Cell cycle synchronization to detect cell cycle-dependent modifications

These methodological approaches enable researchers to characterize the diverse forms of SPAC57A7.07c that may exist in vivo, providing insights into regulatory mechanisms and functional diversity .

What are the best practices for ensuring reproducibility when using SPAC57A7.07c antibodies across different research groups?

Ensuring reproducibility in antibody-based research requires rigorous methodological standards:

• Comprehensive Antibody Documentation:

  • Record complete antibody information: supplier, catalog number, lot number

  • Document exact dilutions and incubation conditions

  • Maintain detailed protocols including buffer compositions

• Validation Standard Implementation:

  • Employ multiple validation methods as recommended by the International Working Group for Antibody Validation

  • Include genetic knockdown/knockout controls

  • Perform independent validation using orthogonal techniques

• Standardized Experimental Controls:

  • Include consistent positive and negative controls across experiments

  • Use calibration standards for quantitative comparisons

  • Implement spike-in controls for recovery assessment

• Metadata Reporting Requirements:

  • Follow minimum information guidelines for antibody-based experiments

  • Document cell/tissue processing methods comprehensively

  • Report all optimization steps and failed approaches

• Protocol Sharing Practices:

  • Publish detailed protocols on platforms like protocols.io

  • Share validation data openly with collaborators

  • Deposit raw data in appropriate repositories

By implementing these practices, research groups can significantly improve the reproducibility of SPAC57A7.07c antibody research, enhancing scientific rigor and facilitating cross-laboratory validation .

How can researchers integrate multi-omics approaches with antibody-based detection to comprehensively characterize SPAC57A7.07c function?

Integrating multi-omics with antibody-based research provides powerful insights:

• Coordinated Experimental Design:

  • Collect samples simultaneously for antibody-based detection and omics analysis

  • Implement consistent perturbation conditions across methodologies

  • Design temporal sampling to capture dynamic processes

• Complementary Technology Integration:

  • Transcriptomics: Correlate protein levels (antibody detection) with mRNA expression

  • Proteomics: Validate antibody results with mass spectrometry-based identification

  • Interactomics: Combine antibody-based co-IP with proximity labeling techniques

  • Metabolomics: Connect metabolic changes with SPAC57A7.07c expression/modification

• Data Integration Framework:

  • Use computational approaches to correlate datasets across platforms

  • Implement network analysis to place SPAC57A7.07c in functional context

  • Develop visualization tools for multi-dimensional data presentation

• Validation Strategy:

  • Use orthogonal methods to confirm key findings

  • Design targeted experiments to test hypotheses from omics data

  • Implement genetic perturbations to establish causality

• Functional Characterization:

  • Map antibody-detected protein changes to pathway alterations

  • Connect post-translational modifications with functional outcomes

  • Correlate localization changes with metabolic adaptations